SCHEDULE 13G/A: BlackRock Amends Stake in Coherus BioSciences, Disclosing 6.6% Beneficial Ownership
Beneficial Ownership Report
BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 6.6% beneficial ownership stake in Coherus BioSciences Inc. as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 7,617,701 shares of Coherus BioSciences Inc. common stock.
- This ownership represents 6.6% of the total outstanding common stock of Coherus BioSciences Inc.
- BlackRock holds sole voting power over 7,509,801 shares.
- BlackRock holds sole dispositive power over 7,617,701 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Investment Management, LLC, are involved in the beneficial ownership, with BlackRock Investment Management, LLC beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing (Schedule 13G Amendment), which is purely factual and discloses passive ownership. It contains no positive or negative operational news about the issuer, hence a neutral sentiment score.
Industry Context
This filing is a routine disclosure by a major institutional investor, BlackRock, regarding its passive ownership stake in a publicly traded biotechnology company, Coherus BioSciences Inc. Such filings are common and reflect portfolio management activities rather than specific strategic moves related to the issuer's operations.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming BlackRock's continued passive investment in Coherus BioSciences Inc.
Key Dates
| Date | Description |
|---|---|
| 2025-01-21 | Date of execution for the Power of Attorney document. |
| 2025-03-31 | Date of event which requires the filing of this statement, indicating the reporting period end. |
| 2025-04-17 | Date of signature for the Schedule 13G filing. |
Keywords
BlackRock, Coherus BioSciences, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.